{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:28:45Z","timestamp":1793838525991,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Lantern Pharma Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10637-026-01626-y","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:11:36Z","timestamp":1783383096000},"page":"371-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"44","author":[{"given":"Daruka","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Willam B.","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisa C.","family":"Schreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misty D.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce B.","family":"Bank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Ewesuedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"1626_CR1","unstructured":"Alkylating Agents. In: LiverTox: clinical and research information on drug-induced liver injury. [Updated 2015 Mar 10].  https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547849\/. Accessed 5 Mar 2026"},{"key":"1626_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1101\/gad.349431.122","volume":"36","author":"JL Hopkins","year":"2022","unstructured":"Hopkins JL, Lan L, Zou L (2022) DNA repair defects in cancer and therapeutic opportunities. Genes Dev 36:278\u2013293","journal-title":"Genes Dev"},{"key":"1626_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cr.2008.6","volume":"18","author":"M Fousteri","year":"2008","unstructured":"Fousteri M, Mullenders LH (2008) Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res 18:73\u201384","journal-title":"Cell Res"},{"key":"1626_CR4","first-page":"86","volume":"39","author":"A Khalizieva","year":"2025","unstructured":"Khalizieva A, Moser SC, Bouwman P, Jonkers J (2025) BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality. Genes Dev 39:86\u2013108","journal-title":"Genes Dev"},{"key":"1626_CR5","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419","journal-title":"Science"},{"key":"1626_CR6","doi-asserted-by":"publisher","first-page":"1033395","DOI":"10.3389\/fddsv.2022.1033395","volume":"2","author":"J McDermott","year":"2022","unstructured":"McDermott J, Sturtevant D, Kathad U et al (2022) Artificial intelligence platform, RADR\u00ae, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors. Front Drug Discov 2:1033395","journal-title":"Front Drug Discov"},{"key":"1626_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.717730","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Yin G, Zhang W, Song K, Zhang L, Guo Z (2021) Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy. Front Pharmacol 12:717730","journal-title":"Front Pharmacol"},{"key":"1626_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/1535-7163.MCT-22-0818","volume":"22","author":"D Restifo","year":"2023","unstructured":"Restifo D, McDermott JR, Cvetkovic D et al (2023) Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies. Mol Cancer Ther 22:1182\u20131190","journal-title":"Mol Cancer Ther"},{"key":"1626_CR9","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1158\/1078-0432.CCR-23-0673","volume":"29","author":"B Lal","year":"2023","unstructured":"Lal B, Kulkarni A, McDermott J et al (2023) Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma. Clin Cancer Res 29:4209\u20134218","journal-title":"Clin Cancer Res"},{"key":"1626_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1626_CR11","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41:5187\u20135199","journal-title":"J Clin Oncol"},{"key":"1626_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/rssc.12089","volume":"64","author":"S Liu","year":"2015","unstructured":"Liu S, Yuan Y (2015) Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc: Ser C (Appl Stat) 64:507\u201323","journal-title":"J R Stat Soc: Ser C (Appl Stat)"},{"key":"1626_CR13","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. November 27, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"1626_CR14","doi-asserted-by":"crossref","unstructured":"Kulkarni A, Zhou J, Agnello G et al Identification of biomarkers for drug candidate LP-184 in precision oncology applications. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25\u201330; Chicago, IL","DOI":"10.1158\/1538-7445.AM2025-2033"},{"issue":"3","key":"1626_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12029-024-01059-x","volume":"55","author":"J Li","year":"2024","unstructured":"Li J, Wang W, Jiang K et al (2024) Risk factors of chemotherapy-induced thrombocytopenia after oxaliplatin-containing chemotherapy for gastrointestinal malignancies. J Gastrointest Cancer 55(3):1144\u20131153","journal-title":"J Gastrointest Cancer"},{"key":"1626_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.biocel.2014.05.017","volume":"53","author":"R S\u00e1nchez-Rodr\u00edguez","year":"2014","unstructured":"S\u00e1nchez-Rodr\u00edguez R, Torres-Mena JE, De-la-Luz-Cruz M et al (2014) Increased expression of prostaglandin reductase 1 in hepatocellular carcinomas from clinical cases and experimental tumors in rats. Int J Biochem Cell Biol 53:186\u2013194","journal-title":"Int J Biochem Cell Biol"},{"issue":"10","key":"1626_CR17","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","volume":"10","author":"J Alexandre","year":"2004","unstructured":"Alexandre J, Raymond E, Kaci MO et al (2004) Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res 10(10):3377\u20133385","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1626_CR18","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1200\/JCO.2000.18.24.4086","volume":"18","author":"SG Eckhardt","year":"2000","unstructured":"Eckhardt SG, Baker SD, Britten CD et al (2000) Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18(24):4086\u20134097","journal-title":"J Clin Oncol"},{"issue":"9863","key":"1626_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295\u2013302","journal-title":"Lancet"},{"issue":"7","key":"1626_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC et al (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7):923\u2013934","journal-title":"Lancet Oncol"},{"issue":"8","key":"1626_CR21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.34678","volume":"129","author":"R Maniar","year":"2023","unstructured":"Maniar R, Loehrer PJ Sr. (2023) Understanding the landscape of immunotherapy in thymic epithelial tumors. Cancer 129(8):1162\u20131172","journal-title":"Cancer"},{"issue":"5","key":"1626_CR22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2767-9764.CRC-23-0554","volume":"4","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni A, Zhou J, Biyani N et al (2024) LP-184, a novel acylfulvene molecule, exhibits anticancer activity against diverse solid tumors with homologous recombination deficiency. Cancer Res Commun 4(5):1199\u20131210","journal-title":"Cancer Res Commun"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01626-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:05:52Z","timestamp":1793837152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01626-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01626-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical standards in the Declaration of Helsinki and applicable Good Clinical Practice guidelines. The study protocol was approved by the appropriate institutional and\/or national research ethics committee.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients or their legal representatives before enrollment.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sponsor (Lantern Pharma Inc.) was involved in the study design, data collection, analysis, interpretation, and manuscript preparation. J.Z, M.C, K.B., and R.E. are salaried employees of Lantern Pharma Inc. and are entitled to hold stock options in the company. J.Z. and K.B. are named inventors on several intellectual properties by Lantern Pharma Inc.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}